Source: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 09; Vol. 25 (16). Date of Electronic Publication: 2024 Aug 09.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants.

Authors : Dauki AM; Gilead Sciences, Inc., Foster City, California, USA.; Rajakumaraswamy N

Subjects: Healthy Volunteers* ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/pharmacokinetics ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage

Source: Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e70011.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space.

Authors : Cloesmeijer ME; Sjögren E ...

Subjects: Collagen Type IV*/Collagen Type IV*/Collagen Type IV*/pharmacokinetics ; Collagen Type IV*/Collagen Type IV*/Collagen Type IV*/metabolism ; Collagen Type IV*/Collagen Type IV*/Collagen Type IV*/administration & dosage

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Oct; Vol. 13 (10), pp. 1630-1640. Date of Electronic Publication: 2024 Sep 16.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.

Authors : Han J; Lilly Korea Ltd., Seoul, Korea.; Lee WJ

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use

Source: Diabetes & metabolism journal [Diabetes Metab J] 2024 May; Vol. 48 (3), pp. 418-428. Date of Electronic Publication: 2024 Feb 02.Publisher: Korean Diabetes Association Country of Publication: Korea (South) NLM ID: 101556588 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Exploiting the Fc base of IgG antibodies to create functional nanoparticle conjugates.

Authors : Al Qaraghuli MM; EPSRC Future Manufacturing Research Hub for Continuous Manufacturing and Advanced Crystallisation, University of Strathclyde, Glasgow, UK. .; SiMologics Ltd. The Enterprise Hub, Level 6 Graham Hills Building, 50 Richmond Street, Glasgow, G1 1XP, UK. .

Subjects: Immunoglobulin G*/Immunoglobulin G*/Immunoglobulin G*/chemistry ; Immunoglobulin G*/Immunoglobulin G*/Immunoglobulin G*/immunology ; Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/chemistry

Source: Scientific reports [Sci Rep] 2024 Jun 27; Vol. 14 (1), pp. 14832. Date of Electronic Publication: 2024 Jun 27.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.

Authors : Pierre CN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Duke University School of Medicine, Durham, North Carolina, United States of America.

Subjects: SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/immunology ; COVID-19*/COVID-19*/COVID-19*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control

Source: PLoS pathogens [PLoS Pathog] 2024 Jun 20; Vol. 20 (6), pp. e1011569. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.

Authors : Gao X; Sunshine Lake Pharma Co., Ltd., Dongguan, Guangdong, China.; Di Y

Source: Clinical and translational science [Clin Transl Sci] 2024 Apr; Vol. 17 (4), pp. e13775.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Using atomistic solution scattering modelling to elucidate the role of the Fc glycans in human IgG4.

Authors : Spiteri VA; Division of Biosciences, Department of Structural and Molecular Biology, University College London, London, United Kingdom.; Doutch J

Subjects: Immunoglobulin G*/Immunoglobulin G*/Immunoglobulin G*/chemistry ; Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/chemistry; Humans

Source: PloS one [PLoS One] 2024 Apr 01; Vol. 19 (4), pp. e0300964. Date of Electronic Publication: 2024 Apr 01 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.

Authors : Jin M; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.

Subjects: Depression*/Depression*/Depression*/drug therapy ; Antidepressive Agents*/Antidepressive Agents*/Antidepressive Agents*/pharmacology ; Antidepressive Agents*/Antidepressive Agents*/Antidepressive Agents*/therapeutic use

Source: Brain and behavior [Brain Behav] 2024 Mar; Vol. 14 (3), pp. e3448.Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101570837 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.

Authors : Kimura T; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.; Kubo M

Source: Journal of diabetes research [J Diabetes Res] 2024 Jan 04; Vol. 2024, pp. 5880589. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2024).Publisher: Hindawi Limited Country of Publication: England NLM ID: 101605237 Publication Model: eCollection Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Virtual Screening and Validation of Affinity DNA Functional Ligands for IgG Fc Segment.

Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants.

PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space.

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.

Exploiting the Fc base of IgG antibodies to create functional nanoparticle conjugates.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.

Using atomistic solution scattering modelling to elucidate the role of the Fc glycans in human IgG4.

Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.

اتصل بنا

اتبع